Impact ledger
CRISPR Therapeutics AG (CRSP): the developments shaping its investment case
Follow the evidence affecting CRISPR Therapeutics AG. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research CRISPR Therapeutics AG · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-09 · 3 reports
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Channel: Direct commercial success and regulatory approval for key product. Increased market penetration and addressable patient population.
Bullish· 3-12m
2026-09-09
FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
Channel: Direct expansion of addressable market for flagship product, leading to increased sales volume and revenue growth.
Bullish· 3-12m
2026-09-09
CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
Channel: Direct product sales growth and expanded market opportunity
Bullish· 1-3m
Event impact log
11 events mapped to CRSP since 2026-09-09. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | uniQure N.V. Reports 48-Month Data for AMT-130 in Huntington’s Disease | Indirect impact on investor sentiment for the broader gene editing/gene therapy sector. Positive clinical data for any gene therapy can bolster confidence in the overall modality, but also highlight competitive pressures. | mixed | 1-3m | 0.20 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Indirect positive sentiment for the broader synthetic biology and gene editing sector, potential for increased investor interest in platform technologies. | Bullish | 3-12m | 0.30 |
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Indirect benefit from overall market expansion and increased investor interest in cell therapy, particularly as 'allogeneic pipelines advance', given their focus on CRISPR-edited cell therapies for oncology. | Bullish | 1-5y | 0.40 |
| 2026-09-12 | Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline | Second-order effect: Investor sentiment and competitive landscape in the gene editing and CAR T space. Positive or negative news from Cellectis could spill over to peers. | mixed | 1-3m | 0.30 |
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space. | watch | 1-5d | 0.30 |
| 2026-09-12 | Cellectis sets September 14 business update on CAR-T and gene editing pipeline | Indirect sector sentiment; Cellectis's gene editing updates could influence broader investor sentiment towards gene editing technologies. | watch | 1-5d | 0.20 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Direct commercial success and regulatory approval for key product. Increased market penetration and addressable patient population. | Bullish | 3-12m | 0.90 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+ | Direct expansion of addressable market for flagship product, leading to increased sales potential. | Bullish | 3-12m | 0.80 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Direct revenue generation from expanded market access and strong initial commercialization traction for Casgevy. | Bullish | 1-3m | 0.80 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Direct expansion of addressable market for flagship product, leading to increased sales volume and revenue growth. | Bullish | 3-12m | 0.90 |
| 2026-09-09 | CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M | Direct product sales growth and expanded market opportunity | Bullish | 1-3m | 0.90 |
Continue this research
Build your CRISPR Therapeutics AG investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the CRSP entity page →